细胞因子在骨髓增殖性肿瘤中的治疗与预后的影响
The Impact of Cytokines on Treatment and Prognosis in Myeloproliferative Neoplasms
DOI: 10.12677/jcpm.2026.51029, PDF,   
作者: 尹 创*, 黄 彬, 董迎盈, 庞 缨#：广州医科大学附属第二医院血液科，广东 广州
关键词: 细胞因子；骨髓纤维化；JAK2-V617F；CALR基因突变；靶向治疗；Cytokines； Myelofibrosis； JAK2-V617F； CALR Mutations； Targeted Therapy
摘要: 骨髓增殖性肿瘤(Myeloproliferative neoplasms, MPN)是一类由造血干细胞基因突变引起的恶性疾病，主要包括真性红细胞增多症、原发性血小板增多症和骨髓纤维化。近年来，细胞因子(如IL-6、IL-10等)在MPN中的作用引起了广泛关注。这些细胞因子不仅在肿瘤微环境中发挥着关键作用，还与疾病的临床表现、治疗反应及预后密切相关。本文综述了细胞因子在MPN中的表达水平及其与疾病进展的关联，探讨了针对这些细胞因子的治疗策略，包括使用单克隆抗体和小分子抑制剂等新兴疗法的临床试验结果。此外，我们还分析了细胞因子作为生物标志物在疾病监测和预后评估中的潜力。通过系统综述现有文献，我们希望为MPN的综合治疗方案提供新的见解，并强调靶向细胞因子的治疗在改善患者预后方面的前景。
Abstract: Myeloproliferative neoplasms (MPN) are a group of malignant diseases caused by mutations in hematopoietic stem cell genes, primarily including polycythemia vera, essential thrombocythemia, and myelofibrosis. In recent years, the role of cytokines (such as IL-6, IL-10, etc.) in MPN has gained extensive attention. These cytokines play a crucial role in the tumor microenvironment and are closely related to the clinical manifestations, treatment responses, and prognosis of the disease. This review summarizes the expression levels of cytokines in MPN and their association with disease progression. It explores therapeutic strategies targeting these cytokines, including clinical trial results of emerging therapies such as monoclonal antibodies and small molecule inhibitors. Additionally, we analyze the potential of cytokines as biomarkers for disease monitoring and prognosis evaluation. By systematically reviewing existing literature, we aim to provide new insights into comprehensive treatment strategies for MPN and emphasize the prospects of cytokine-targeted therapies in improving patient prognosis.
文章引用：尹创, 黄彬, 董迎盈, 庞缨. 细胞因子在骨髓增殖性肿瘤中的治疗与预后的影响[J]. 临床个性化医学, 2026, 5(1): 193-201. https://doi.org/10.12677/jcpm.2026.51029

参考文献

[1] Morris, R., Kershaw, N.J. and Babon, J.J. (2018) The Molecular Details of Cytokine Signaling via the JAK/STAT Pathway. Protein Science, 27, 1984-2009. [Google Scholar] [CrossRef] [PubMed]
[2] Greenfield, G., McMullin, M.F. and Mills, K. (2021) Molecular Pathogenesis of the Myeloproliferative Neoplasms. Journal of Hematology & Oncology, 14, Article No. 103. [Google Scholar] [CrossRef] [PubMed]
[3] Bjørn, M.E. and Hasselbalch, H.C. (2015) The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms. Mediators of Inflammation, 2015, Article ID: 648090. [Google Scholar] [CrossRef] [PubMed]
[4] Li, Y., Sun, T., Chen, J. and Zhang, L. (2024) Identification of Novel Risk Variants of Inflammatory Factors Related to Myeloproliferative Neoplasm: A Bidirectional Mendelian Randomization Study. Global Medical Genetics, 11, 48-58. [Google Scholar] [CrossRef] [PubMed]
[5] Popek-Marciniec, S., Styk, W., Wojcierowska-Litwin, M., Szudy-Szczyrek, A., Dudek, P., Swiderska-Kolacz, G., et al. (2023) The Relationship of CCL5 and CCR1 Variants with Response Rate and Survival Taking into Account Thalidomide/Bortezomib Treatment in Patients with Multiple Myeloma. Journal of Clinical Medicine, 12, Article 2384. [Google Scholar] [CrossRef] [PubMed]
[6] Verstovsek, S., Mesa, R.A., Livingston, R.A., Hu, W. and Mascarenhas, J. (2023) Ten Years of Treatment with Ruxolitinib for Myelofibrosis: A Review of Safety. Journal of Hematology & Oncology, 16, Article No. 82. [Google Scholar] [CrossRef] [PubMed]
[7] Verstovsek, S., Mesa, R.A., Gotlib, J., Gupta, V., DiPersio, J.F., Catalano, J.V., et al. (2017) Long-Term Treatment with Ruxolitinib for Patients with Myelofibrosis: 5-Year Update from the Randomized, Double-Blind, Placebo-Controlled, Phase 3 COMFORT-I Trial. Journal of Hematology & Oncology, 10, Article No. 55. [Google Scholar] [CrossRef] [PubMed]
[8] Vannucchi, A.M., Kiladjian, J.J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., et al. (2015) Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera. New England Journal of Medicine, 372, 426-435. [Google Scholar] [CrossRef] [PubMed]
[9] Rai, S., Grockowiak, E., Hansen, N., Luque Paz, D., Stoll, C.B., Hao-Shen, H., et al. (2022) Inhibition of Interleukin-1β Reduces Myelofibrosis and Osteosclerosis in Mice with JAK2-V617F Driven Myeloproliferative Neoplasm. Nature Communications, 13, Article No. 5346. [Google Scholar] [CrossRef] [PubMed]
[10] 沙巴艾提∙吐达洪, 庞楠楠, 谢仁古丽∙阿力木, 等. Th9细胞及其细胞因子IL-9在慢性淋巴细胞白血病中的表达及临床意义[J]. 中国实验血液学杂志, 2023, 31(6): 1663-1669.
[11] 满艳, 葛传琴, 李增政, 等. 细胞因子在初诊弥漫大B细胞淋巴瘤患者中的表达及其预后价[J]. 中国实验血液学杂志, 2023, 31(4): 1050-1055.
[12] 严志民, 刘彦权, 黄走方, 等. T细胞亚群与细胞因子水平变化在多发性骨髓瘤患者临床诊疗及预后评估中的价值[J]. 中国实验血液学杂志, 2022, 30(6): 1791-1796.
[13] Kleppe, M., Kwak, M., Koppikar, P., Riester, M., Keller, M., Bastian, L., et al. (2015) JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response. Cancer Discovery, 5, 316-331. [Google Scholar] [CrossRef] [PubMed]
[14] Øbro, N.F., Grinfeld, J., Belmonte, M., Irvine, M., Shepherd, M.S., Rao, T.N., et al. (2020) Longitudinal Cytokine Profiling Identifies Gro‐α and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia. HemaSphere, 4, e371. [Google Scholar] [CrossRef] [PubMed]
[15] 高亚梅, 贡蓉, 白波. 费城染色体阴性骨髓增殖性肿瘤驱动基因突变和细胞因子表达的相关研究[J]. 临床血液学杂志, 2023, 36(6): 427-432.
[16] 马骏, 瞿文, 陶景莲, 等. IL-9和IL-6在BCR-ABL-MPN患者中的表达及其意义[J]. 中国实验血液学杂志, 2020, 28(5): 1661-1667.
[17] Woo, J., Lu, D., Lewandowski, A., Xu, H., Serrano, P., Healey, M., et al. (2023) Effects of Il-1β Inhibition on Anemia and Clonal Hematopoiesis in the Randomized CANTOS Trial. Blood Advances, 7, 7471-7484. [Google Scholar] [CrossRef] [PubMed]
[18] Verstovsek, S., Foltz, L., Gupta, V., Hasserjian, R., Manshouri, T., Mascarenhas, J., et al. (2023) Safety and Efficacy of Zinpentraxin Alfa as Monotherapy or in Combination with Ruxolitinib in Myelofibrosis: Stage I of a Phase II Trial. Haematologica, 108, 2730-2742. [Google Scholar] [CrossRef] [PubMed]
[19] Mesa, R.A., Hudgens, S., Floden, L., Harrison, C.N., Palmer, J., Gupta, V., et al. (2023) Symptomatic Benefit of Momelotinib in Patients with Myelofibrosis: Results from the simplify Phase III Studies. Cancer Medicine, 12, 10612-10624. [Google Scholar] [CrossRef] [PubMed]
[20] Gerds, A.T., Verstovsek, S., Vannucchi, A.M., Al-Ali, H.K., Lavie, D., Kuykendall, A.T., et al. (2023) Momelotinib versus Danazol in Symptomatic Patients with Anaemia and Myelofibrosis Previously Treated with a JAK Inhibitor (MOMENTUM): An Updated Analysis of an International, Double-Blind, Randomised Phase 3 Study. The Lancet Haematology, 10, e735-e746. [Google Scholar] [CrossRef] [PubMed]
[21] Mascarenhas, J., Kremyanskaya, M., Patriarca, A., Palandri, F., Devos, T., Passamonti, F., et al. (2023) MANIFEST: Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis. Journal of Clinical Oncology, 41, 4993-5004. [Google Scholar] [CrossRef] [PubMed]
[22] Gupta, V., Mascarenhas, J., Kremyanskaya, M., Rampal, R.K., Talpaz, M., Kiladjian, J., et al. (2023) Matching-Adjusted Indirect Comparison of the Pelabresib-Ruxolitinib Combination vs Jaki Monotherapy in Myelofibrosis. Blood Advances, 7, 5421-5432. [Google Scholar] [CrossRef] [PubMed]
[23] Isfort, S., von Bubnoff, N., Al-Ali, H.K., Becker, H., Götze, T., le Coutre, P., et al. (2024) FRACTION: Protocol of a Phase II Study of Fedratinib and Nivolumab Combination in Patients with Myelofibrosis and Resistance or Suboptimal Response to Jak-Inhibitor Treatment of the German MPN Study Group (GSG-MPN). Annals of Hematology, 103, 2775-2785. [Google Scholar] [CrossRef] [PubMed]
[24] Kucine, N., Jessup, J.A., Cooper, T.M., Urbanski, R.W., Kolb, E.A. and Resar, L.M.S. (2023) Position Paper: The Time for Cooperative Group Study of Ropeginterferon Alfa‐2b in Young Patients with Myeloproliferative Neoplasms Is Now. Pediatric Blood & Cancer, 70, e30559. [Google Scholar] [CrossRef] [PubMed]
[25] Bose, P., Xiao, Z., Hasselbalch, H.C., Prchal, J.T., Duan, M., Yacoub, A., et al. (2025) Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms. Current Hematologic Malignancy Reports, 20, Article No. 9. [Google Scholar] [CrossRef] [PubMed]
[26] Sørensen, A.L., Skov, V., Kjær, L., Bjørn, M.E., Eickhardt-Dalbøge, C.S., Larsen, M.K., et al. (2024) Combination Therapy with Ruxolitinib and Pegylated Interferon Alfa-2a in Newly Diagnosed Patients with Polycythemia Vera. Blood Advances, 8, 5416-5425. [Google Scholar] [CrossRef] [PubMed]
[27] Peroni, E., Calistri, E., Amato, R., Gottardi, M. and Rosato, A. (2024) Spatial-Transcriptomic Profiling: A New Lens for Understanding Myelofibrosis Pathophysiology. Cell Communication and Signaling, 22, Article No. 510. [Google Scholar] [CrossRef] [PubMed]
[28] Cannarile, M.A., Weisser, M., Jacob, W., Jegg, A., Ries, C.H. and Rüttinger, D. (2017) Colony-Stimulating Factor 1 Receptor (CSF1R) Inhibitors in Cancer Therapy. Journal for ImmunoTherapy of Cancer, 5, Article No. 53. [Google Scholar] [CrossRef] [PubMed]
[29] Sockolosky, J.T., Trotta, E., Parisi, G., Picton, L., Su, L.L., Le, A.C., et al. (2018) Selective Targeting of Engineered T Cells Using Orthogonal IL-2 Cytokine-Receptor Complexes. Science, 359, 1037-1042. [Google Scholar] [CrossRef] [PubMed]
[30] Verstovsek, S., Mesa, R.A., Gotlib, J., Levy, R.S., Gupta, V., DiPersio, J.F., et al. (2012) A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. New England Journal of Medicine, 366, 799-807. [Google Scholar] [CrossRef] [PubMed]